Reverse molecular pharmacology identifies the non-canonical axis of IRAK as a chemoresistance factor in neuroblastoma
Marion Le Grand, Chen Buxbaum, Mathilde Kerhervé, Flavie Gaucher, Alvaro A. Martinez, Mohammed Taha, Kévin Müller, Baptiste Mouysset, Alexandra Bomane, Sébastien Letard, Tim W. Failes, Greg M. Arndt, Seimia Chebbi, Emmanuel Labaronne, Florence M.G. Cavalli, , Eddy Pasquier
This study identifies IRAK1 as a chemoresistance factor in neuroblastoma and shows synergy between IRAK1 inhibition and various drugs in preclinical models.
bioRxiv · Jan 9, 2026 · PreprintCancer Biology